Personalis (NASDAQ:PSNL) CFO Sells 2,931 Shares

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 2,931 shares of the firm’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $16.22, for a total value of $47,540.82. Following the sale, the chief financial officer directly owned 195,902 shares in the company, valued at approximately $3,177,530.44. This represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Aaron Tachibana also recently made the following trade(s):

• On Monday, June 29th, Aaron Tachibana sold 4,982 shares of Personalis stock. The stock was sold at an average price of $14.00, for a total value of $69,748.00.
• On Friday, June 26th, Aaron Tachibana sold 51,251 shares of Personalis stock. The stock was sold at an average price of $13.18, for a total value of $675,488.18.

Personalis Trading Up 0.7%

PSNL traded up $0.12 on Tuesday, hitting $16.36. 1,369,078 shares of the company’s stock traded hands, compared to its average volume of 2,690,633. The company’s 50 day simple moving average is $15.06 and its 200-day simple moving average is $10.89. Personalis, Inc. has a one year low of $4.95 and a one year high of $18.89. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -15.01 and a beta of 2.31.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%.The business had revenue of $22.36 million during the quarter, compared to the consensus estimate of $16.69 million. As a group, equities analysts anticipate that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Institutional Trading of Personalis

Several institutional investors have recently added to or reduced their stakes in PSNL. Merck & Co. Inc. bought a new stake in Personalis in the second quarter worth about $188,202,236. BlackRock Inc. purchased a new stake in shares of Personalis in the second quarter worth approximately $94,905,000. Bank of America Corp DE purchased a new stake in shares of Personalis in the second quarter worth approximately $24,395,000. AIGH Capital Management LLC bought a new stake in shares of Personalis during the 2nd quarter worth approximately $22,981,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Personalis by 8.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock worth $6,791,000 after acquiring an additional 83,074 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Morgan Stanley lifted their price target on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. BTIG Research raised their price objective on Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a research report on Monday, July 20th. TD Cowen reiterated a “buy” rating on shares of Personalis in a research report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Friday, July 17th. Finally, Zacks Research raised shares of Personalis from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $14.54.

About Personalis

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.